Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New devices aim to ease cold symptoms – but will they work?

NCT ID NCT07383493

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing four medical devices (PIR, NS, NHE, NHG) in 150 adults with acute viral rhinitis, rhinosinusitis, or rhinopharyngitis (common cold). The goal is to see if they are safe and help reduce symptoms like sneezing, runny nose, and sore throat. Participants use the device for up to 14 days and report any side effects and symptom changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
medical devices (PIR, NS, NHE, NHG)
What this could lead to
If successful, this could confirm that these devices safely reduce symptoms like runny nose and congestion for people with common colds.
What could go wrong
This is a small, early-stage study with no placebo group, so results may not prove the devices work better than doing nothing. Side effects are possible but not well understood yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment, * Effective contraception for female patients of childbearing age. * Cooperation and sufficient understanding to comply with the requirements of the trial. * Acceptance of registration in the SI-RIPH VRB file. * Having received informed information and agreeing to give written consent. * Affiliated with the French Social Security system. Exclusion Criteria: * Hypersensitivity/history of allergy to any of the product's components, * Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated, * Chronic rhinosinusitis, * Allergic rhinosinusitis, * Other ongoing treatments for acute rhinitis (local treatment, antitussives, antibiotics, antiretrovirals, corticosteroids, etc.), * Positive antigen test for influenza A/B or COVID-19 and infection requiring etiological treatment according to the recommendations, * Bacterial rhinopharyngitis with positive TROD test * Comorbidities or health conditions deemed incompatible with the trial by the investigator, * Recent ENT surgery (\<6 months), * ENT pathology such as nasal septum deviation or other causes of nasal obstruction, * Pulmonary pathology (COPD, asthma, etc.), * Immunosuppression (as reported by the patient), * Pregnant or breastfeeding women, * Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial, * Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Plateforme d'investigation clinique/Centre d'Investigation Clinique, Inserm CIC 1405

    RECRUITING

    Clermont-Ferrand, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.